Prices delayed by at least 15 minutes | Print
Esperion Therapeutics (ESPR)
Common SharesThis share can be held in a Dealing accountISALifetime ISAJISASIPP
Company profile
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
Address
3891 Ranchero Drive
Suite 150
Ann Arbor
MI
USA
48108
Telephone
+1 734 887-3903
Forecast key dates
| Name | Key Date |
|---|---|
| Esperion Therapeutics Inc Fourth Quarter Earnings Conference Call for 2024 | 2025-02-27T08:00:00 |
| Esperion Therapeutics Inc Fourth Quarter Earnings Results for 2024 | 2025-02-27T00:00:00 |
| Esperion Therapeutics Inc Annual Report for 2024 | 2025-02-27T00:00:00 |
| Esperion Therapeutics Inc Third Quarter Earnings Conference Call for 2024 | 2024-11-07T08:00:00 |
| Esperion Therapeutics Inc Third Quarter Earnings Results for 2024 | 2024-11-07T00:00:00 |
| Esperion Therapeutics Inc Second Quarter Earnings Conference Call for 2024 | 2024-08-01T08:00:00 |
| Esperion Therapeutics Inc Second Quarter Earnings Results for 2024 | 2024-08-01T00:00:00 |
| Esperion Therapeutics Inc Annual General Meeting for 2024 | 2024-05-24T08:00:00 |
| Esperion Therapeutics Inc First Quarter Earnings Conference Call for 2024 | 2024-05-07T08:00:00 |
| Esperion Therapeutics Inc First Quarter Earnings Result for 2024 | 2024-05-07T00:00:00 |
| Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference | 2024-04-09T12:45:00 |
Previous key dates
| Name | Key Date |
|---|---|
| Esperion to Participate in 23rd Annual Needham Virtual Healthcare Conference | 2024-04-09T12:45:00 |
| Esperion Therapeutics Inc Fourth Quarter Earnings Conference Call for 2023 | 2024-02-27T08:00:00 |
| Esperion Therapeutics Inc Fourth Quarter Earnings Result for 2023 | 2024-02-27T00:00:00 |
| Esperion Therapeutics Inc Annual Report for 2023 | 2024-02-27T00:00:00 |
| Esperion Therapeutics Inc Third Quarter Earnings Conference Call for 2023 | 2023-11-07T08:00:00 |
| Esperion Therapeutics Inc Third Quarter Earnings Result for 2023 | 2023-11-07T00:00:00 |
| Esperion Therapeutics Inc Second Quarter Earnings Conference Call for 2023 | 2023-08-01T08:00:00 |
| Esperion Therapeutics Inc Second Quarter Earnings Result for 2023 | 2023-08-01T00:00:00 |
| Esperion Therapeutics Inc Annual General Meeting for 2023 | 2023-05-25T08:00:00 |
| Esperion Therapeutics Inc First Quarter Earnings Conference Call for 2023 | 2023-05-09T08:00:00 |
| Esperion Therapeutics Inc First Quarter Earnings Result for 2023 | 2023-05-09T00:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2024 AJ Bell. All rights reserved.